Table 2

Expressions of IFN-γ, IL-4, IL-2, and IL-17 on CD4⁺ subpopulations from untreated new-onset lupus patients and healthy controls

IFN-γ, %

IL-4, %

IL-2, %

IL-17, %

UNOL

HC

UNOL

HC

UNOL

HC

UNOL

HC

CD4⁺ CD25^- Foxp3⁺

7.56 ± 1.23

5.79 ± 1.05

2.97 ± 0.83

2.02 ± 0.83

3.59 ± 1.95

5.09 ± 1.95

4.61 ± 1.54

1.54 ± 1.02

CD4⁺ CD25⁺ Foxp3⁺

0.72 ± 0.34

1.22 ± 0.58

0.39 ± 0.37

0.88 ± 0.37

0.73 ± 0.49

0.22 ± 0.49

0.38 ± 0.32

0.08 ± 0.06

CD4⁺ CD25⁺ Foxp3^-

16.43 ± 3.51

16.81 ± 3.97

13.15 ± 2.99

12.94 ± 2.99

20.41 ± 4.91

19.91 ± 4.91

5.58 ± 1.51

2.37 ± 1.51

CD4⁺ CD25^- Foxp3^-

3.54 ± 1.05

5.92 ± 1.57

0.94 ± 0.56

0.66 ± 0.56

2.92 ± 1.42

8.22 ± 1.42

0.49 ± 0.35

0.67 ± 0.42

Values are presented as mean ± standard deviation. HC: healthy controls; IFN-γ: interferon-gamma; IL: interleukin; UNOL: patients with untreated new-onset lupus.

Yang et al. Arthritis Research & Therapy 2009 11:R153   doi:10.1186/ar2829